Evidence map›Paper›PMID 37569304›Full record

ArticleInternational journal of molecular sciences2023

Dysbindin Domain-Containing 1 in Prostate Cancer: New Insights into Bioinformatic Validation of Molecular and Immunological Features.

Van Thi Ngoc Tram, Hoang Dang Khoa Ta, Gangga Anuraga, Phan Vu Thuy Dung, Do Thi Minh Xuan, Sanskriti Dey, Chih-Yang Wang, Yen-Nien Liu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Van Thi Ngoc TramInternational Ph.D. Program in Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan.
Hoang Dang Khoa TaGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan.ORCID 0000-0001-8809-239X
Gangga AnuragaGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan.ORCID 0000-0002-0902-3968
Phan Vu Thuy DungGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan.
Do Thi Minh XuanGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan.
Sanskriti DeyGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan.
Chih-Yang WangGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan.ORCID 0000-0002-4137-5074
Yen-Nien LiuGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan.ORCID 0000-0002-3102-8482
Taipei Medical University · TWUniversitas PGRI Semarang · IDUniversity Medical Center HCMC · VN

Funding

1. National Science and Technology Council, Taiwan 2. National Health Research Institutes, Taiwan 3. TMU Research Center of Cancer Translational Medicine 1. MOST109-2326-B-038-001-MY3 2. MOST111-2628-B-038-016-MY3
6 · The paper itself

Abstract

Prostate cancer (PCa) is one of the most prevalent cancers in men, yet its pathogenic pathways remain poorly understood. Transcriptomics and high-throughput sequencing can help uncover cancer diagnostic targets and understand biological circuits. Using prostate adenocarcinoma (PRAD) datasets of various web-based applications (GEPIA, UALCAN, cBioPortal, SR Plot, hTFtarget, Genome Browser, and MetaCore), we found that upregulated dysbindin domain-containing 1 (

Indexed as

Computational BiologyProstatic NeoplasmsBiomarkers, TumorDNA MethylationGene Expression Regulation, NeoplasticHumansMaleBiomarkers, Tumorbioinformatic investigationcell cycleDBNDD1 gene expressiondysbindin protein family genesE2FGSK-3βimmunologymicrotubule cytoskeletonprostate cancertumor-infiltrating immune cell

Identifiers

PMID37569304
PMCPMC10418609
OpenAlexW4385278765

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.